For docetaxel, a well-established clinically anti-mitotic chemotherapy medication that works by interfering with cell division, the gene TOP2A, which encodes the key enzyme involved in DNA replication was proposed as the marker gene most relevant to docetaxel-resistance in breast cancer patients. Here, TOP2A is linked to breast cancer.